Skip to main content

Ambrx Biopharma, Inc. (AMAM)

NYSE: AMAM · IEX Real-Time Price · USD
15.46 0.06 (0.39%)
Sep 20, 2021 10:18 AM EDT - Market open
Market Cap582.37M
Revenue (ttm)13.67M
Net Income (ttm)-16.54M
Shares Out37.67M
EPS (ttm)-0.44
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,625
Open15.19
Previous Close15.40
Day's Range15.03 - 15.96
52-Week Range14.94 - 22.87
Betan/a
Analystsn/a
Price Target53.00 (+242.8%)
Est. Earnings Daten/a

About AMAM

Ambrx Biopharma is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using our proprietary expanded genetic code technology platform that allows us to incorporate, in a site-specific manner, synthetic amino acids (SAAs) into proteins within living cells. Our precision engineering capabilities and the broad applicability of our expanded genetic code technology platform have the potential to enhance and enable the therapeutic functions of conventional biologics and bio-...

IndustryBiotechnology
IPO DateJun 18, 2021
CEOFeng Tian, Ph.D.
Employees70
Stock ExchangeNYSE
Ticker SymbolAMAM
Full Company Profile

Financial Performance

In 2020, AMAM's revenue was $13.67 million, an increase of 32.59% compared to the previous year's $10.31 million. Losses were -$16.54 million, -17.54% less than in 2019.

Financial Statements

News

Ambrx to Participate in Panel Discussion at the H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO--(BUSINESS WIRE)--Ambrx to Participate in Panel Discussion at the H.C. Wainwright 23rd Annual Global Investment Conference

1 week ago - Business Wire

Ambrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors

SAN DIEGO--(BUSINESS WIRE)--Ambrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors

1 month ago - Business Wire

Ambrx Appoints Sonja Nelson as Chief Financial Officer

SAN DIEGO--(BUSINESS WIRE)--Ambrx Appoints Sonja Nelson as Chief Financial Officer

2 months ago - Business Wire

Ambrx Announces Pricing of Initial Public Offering

Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics (EPBs), today announced the pricing of its ini...

3 months ago - Business Wire

Ambrx Biopharma IPO Registration Document (S-1)

Ambrx Biopharma, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).

3 months ago - SEC